Galen Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 11-12-2024
- Paid Up Capital ₹ 0.64 M
as on 11-12-2024
- Company Age 34 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.25 Cr
as on 11-12-2024
- Revenue 48.03%
(FY 2022)
- Profit 42.33%
(FY 2022)
- Ebitda 34.88%
(FY 2022)
- Net Worth 44.03%
(FY 2022)
- Total Assets 26.04%
(FY 2022)
About Galen Pharmaceuticals
The Corporate was formerly known as Galen Pharmaceuticals Pvt Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.64 M.
The company currently has active open charges totaling ₹2.25 Cr.
Shardaben Patel, Harsh Patel, Aakash Patel, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232GJ1990PLC013327
- Company No.
013327
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
06 Feb 1990
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Galen Pharmaceuticals Limited offer?
Galen Pharmaceuticals Limited offers a wide range of products and services, including Diclofenac, Diclofenac Sodium Injection, Malaria Medicine, Artesunate Injection, Ointment, Laxatives, Glycerine Suppositories, Anti Cancer Medicines, Ondansetron Hydrochloride Syrup, Digestive System Drugs & Medicines.
Who are the key members and board of directors at Galen Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shardaben Patel  | Director | 06-Feb-1990 | Current |
| Harsh Patel | Director | 08-Mar-2016 | Current |
| Aakash Patel | Director | 14-Feb-2015 | Current |
| Pravinkumar Patel | Director | 06-Feb-1990 | Current |
Financial Performance of Galen Pharmaceuticals.
Galen Pharmaceuticals Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 48.03% increase. The company also saw a substantial improvement in profitability, with a 42.33% increase in profit. The company's net worth Soared by an impressive increase of 44.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Galen Pharmaceuticals?
In 2022, Galen Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 01 Mar 2023 | ₹1.00 M | Open |
Hdfc Bank Limited Creation Date: 01 Aug 2022 | ₹2.00 M | Open |
Bank Of India Creation Date: 28 Dec 2021 | ₹1.35 M | Open |
How Many Employees Work at Galen Pharmaceuticals?
Galen Pharmaceuticals has a workforce of 13 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Galen Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Galen Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
